Having worked with carbohydrate antigens for many years, CD BioGlyco can customize its synthesis according to customers' research needs. We have confidence to be your essential research assistant in the field of glycobiology.
On the surface of cancer cells, abnormal glycosylation occurs, including glycan truncation, neo-glycan expression, and increase/decrease in glycan epitope density. A common aberration in adenocarcinoma is an over-simplification of mucins' glycosylation pattern. Mucins are highly glycosylated proteins and a key component of mucus and other biological lubricants. The tumor-associated carbohydrate antigen (TACA) is a family of oligosaccharides, a subclass of which is expressed on mucin glycopeptides in cancer. ACA can be divided into three categories: the mucin-based glycopeptides (Tn, sialyl-Tn, and TF), lactosamine series expressed as glycoproteins and glycolipids (sialyl Lewisx, Lewisx, sialyl LewisA, and LewisY), and truncated gangliosides (Globo-H, stage-specific embryonic antigen 3, and ganglioside monosialic 2).
The first category has attracted attention due to its relative simplicity and exclusivity to cancer. Although the second category may be used as vaccine targets, their structural complexity limits their use as synthetic vaccines. Gangliosides have shown great potential and may become a rich source of immunological targets in the future. For decades, compared with traditional therapies (chemotherapy and radiotherapy), cancer immunotherapy has great advantages, which has opened the way for the development of TACA molecular design, thereby promoting the development of specific therapies for cancer.
Fig 1. Structures of the most common tumor-associated carbohydrate antigens (Sadraei, S.I.; et al. 2017)
CD BioGlyco has successfully developed several effective strategies to synthesize different types of carbohydrate antigens. The synthesized carbohydrate antigens are verified by nuclear magnetic resonance (NMR) and glycan microarray analysis. And for the shortcomings of low immunogenicity and low metabolic stability of synthetic antigens, we have developed different optimization strategies:
CD BioGlyco can customize different experimental programs to meet the different research needs of customs. The optimized methods we adopted can solve most of the shortcomings of synthetic carbohydrate antigens and provide the best quality products for customers' research.
Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.